Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sarcolysin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.97 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.52 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.52 |
| ▸ | EGFR known ✓ | P00533 | 4/20 | 0.49 |
| ▸ | ERBB2 known ✓ | P04626 | 3/20 | 0.49 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.46 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melphalan SCHEMBL41335 | 1.00 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL11029192 | 1.00 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL28429173 | 0.98 | HIF1A (0.94) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL563239 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL5325132 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| (R)-Melphalan SCHEMBL5873 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL5872 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Sarcolysin SCHEMBL414671 | 0.98 | HIF1A (1.00) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL2723742 | 0.97 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 | |
| Melphalan SCHEMBL4150935 | 0.97 | HIF1A (0.97) | HIF1ACYP3A4ALDH1A1SMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282895-A1 | PHARMACEUTICAL COMPOSITIONS OF CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACID DERIVATIVES | QUADRIGA BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20230348631-A1 | PHARMACEUTICAL COMPOSITIONS OF CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACID DERIVATIVES | QUADRIGA BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116847855-A | Pharmaceutical composition of chemotherapeutic agents based on beta-substituted beta-amino acid derivatives | 夸德里加生物科学公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116047076-A | Method for detecting bacterial endotoxin in melphalan hydrochloride | 广州国标检验检测有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115916225-A | Treatment and prevention of alloreactivity using virus-specific immune cells expressing chimeric antigen receptors | 贝勒医学院 | 2023-04-04 | — | — | CN | disclosed |
| CN-115803092-A | SIRP alpha deficient macrophages for the treatment of cancer | 乔治亚州立大学研究基金公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115397452-A | Lung biomarkers and methods of use thereof | 普罗科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115175903-A | Methods of treating hematological cancers and uses of 2- (2,6-dioxopiperidin-3-yl) -4- ((2-fluoro-4- ((3-morpholinoazetidin-1-yl) methyl) benzyl) amino) isoindoline-1,3-dione associated biomarkers | 新基公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114728022-A | Universal donor selection method for identifying NK cell donors | 全国儿童医院研究所 | 2022-07-08 | — | — | CN | disclosed |
| US-20160016889-A1 | An Improved Process for the Synthesis of Melphalan and the Hydrochloride Salt | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2016-01-21 | — | — | US | disclosed |
| EP-2970102-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF MELPHALAN AND THE HYDROCHLORIDE SALT | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2016-01-20 | — | — | EP | disclosed |
| US-20150160246-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014141294-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF MELPHALAN AND THE HYDROCHLORIDE SALT | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2014-09-18 | — | — | WO | disclosed |
| CN-102030671-B | Preparing method of pharmaceutical melphalam, and hydrochloride and dihydrochloride of pharmaceutical melphalam | ZHEJIANG CHEMPACIFIC CHEMICAL CO LTD | 2014-02-19 | — | — | CN | disclosed |
| US-20120116117-A1 | PROCESS FOR THE PREPARATION OF MELPHALAN HYDROCHLORIDE | EMCURE PHARMACEUTICALS LTD. (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2257558-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | Tatarskiy, Valeriy (DE) | 2010-12-08 | — | — | EP | disclosed |
| EP-2130832-A1 | Copper organic complexes, use thereof as anti-tumour agent and protection of healthy tissue from ionised radiation | Tatarsky, Valeriy, Prof. Dr. (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009103807-A1 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2009-08-27 | — | — | WO | disclosed |
| CN-1370161-A | Novel quaternary ammonium compounds, process for their preparation and their pharmaceutical use | SAVOIER LAB (FR) | 2002-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348631-A1 | PHARMACEUTICAL COMPOSITIONS OF CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACID DERIVATIVES | BCAT1, BCAT2, DDC | PTGS1 3505/4885CHRM2 4266/4885ADRA2A 203/4885 |
| US-20250282895-A1 | PHARMACEUTICAL COMPOSITIONS OF CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACID DERIVATIVES | BCAT1, BCAT2, DDC | PTGS1 3505/4885CHRM2 4266/4885ADRA2A 203/4885 |
| US-20160016889-A1 | An Improved Process for the Synthesis of Melphalan and the Hydrochloride Salt | MCL1, DCPS, MEN1 | PTGS1 3411/4885CHRM2 4742/4885ADRA2A 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.